BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma
- 1 September 2020
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 33 (9), 1660-1668
- https://doi.org/10.1038/s41379-020-0530-3
Abstract
No abstract availableFunding Information
- Japan Agency for Medical Research and Development (JP19ck0106257, JP19lk1403003, JP18kk0205004)
- MEXT | Japan Society for the Promotion of Science (18K15108)
This publication has 50 references indexed in Scilit:
- Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR PathwayPLOS ONE, 2011
- Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcomaJournal of Surgical Oncology, 2011
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapyNature Genetics, 2010
- Synovial sarcomaCancer, 2009
- Phospho-ERK Staining Is a Poor Indicator of the Mutational Status of BRAF and NRAS in Human MelanomaJournal of Investigative Dermatology, 2008
- Drug-sensitiveFGFR2mutations in endometrial carcinomaProceedings of the National Academy of Sciences of the United States of America, 2008
- Primary pulmonary and mediastinal synovial sarcoma: a clinicopathologic study of 60 cases and comparison with five prior seriesLaboratory Investigation, 2007
- Mutations of the BRAF gene in human cancerNature, 2002
- Primary pleuropulmonary synovial sarcomaCancer, 2002